The use of surrogate markers in the antiretroviral treatment of HIV-1 infection
Hill, A.M.

Citation for published version (APA):
Bibliography
BIBLIOGRAPHY

Changing disease patterns in AIDS
Barry S Peters, Diane Coleman, Eduard J Beck, Jeannie F Todd, Janice Main, John R W Harris &
Anthony J Pinching, Andrew Hill

Kaposi's sarcoma in HIV infection treated with vincristine and bleomycin.
Gompels M, Hill AM, Jenkins P et al.

The effect of temperature and duration of storage on the measurement of lymphocyte sub-
populations from HIV-1 positive and control subjects.
Ekong T, Hill AM, Gompels M et al.

Technical influences on immunophenotyping by flow cytometry.
Ekong T, Cupek E, Hill AM et al..

Clinical staging system for AIDS patients
Hill AM..

Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-
containing regimens for patients with HIV-1 infection: the CAESAR trial –
Caesar Co-ordinating Committee [Trial statistician - Andrew Hill]
The LANCET 1996 Vol. 349 No 9063.

Evaluation of safety and efficacy of 3TC (Lamivudine) in patients with asymptomatic or mildly
symptomatic human immunodeficiency virus infection: A phase I/II study - Remko van
Leeuwen, Christine Katlama, Valerie Kitchen, Charles A B Boucher, Roland Tubiana, Michael
McBride, Didier Ingrand, Jonathan Weber, Andrew Hill, Hugh McDade and
Sven A Danner.

Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related
complex patients: sustained reduction in viral markers
Didier Ingrand, Jonathan Weber, Charles AB Boucher, Clive Loveday, Catherine Robert, Andrew
Hill, Nick Cammack and The Lamivudine European HIV Working Group

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral naïve
patients.
Katlama C, Ingrand D, Loveday C, Hill AM et al.
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomised controlled comparison with zidovudine monotherapy-
Schlomo Staszewski, Clive Lovelady, Juan J Picazo, Pierre Dellamonica, Peter Skinhej, Margaret A Johnson, Sven A Danner, P Richard Harrigan, Andrew M Hill; Lucy Verity; Hugh McDade, for the Lamivudine European HIV Working Group.

HIV-1 RNA levels and the development of clinical disease

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS

Modelling the cost-effectiveness of lamivudine/zidovudine combination therapy in HIV infection.
Chancellor J, Hill AM, Sabin C et al

Absence of zidovudine resistance in antiretroviral-naïve patients following zidovudine/lamivudine/protease inhibitor containing therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.
Maguire M, Moore S, Garland M, Hill AM et al.

The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.
M Kilby, A Hill and N Buss.

Peter G. Cardiello; Tarkika Monhaphol; Apicha Mahanontharit; Rolf P. van Heeswijk; David Burger; Andrew Hill; Kiat Ruxrungham; Joe M. Lange; David A. Cooper; Praphan Phanuphak

Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers.
HIV Medicine 2003; 4, 94-100.